3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
8
Neoplasms
4
Neoplasm Metastasis
2
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Lymphoma
1
Lung Neoplasms
1
Liposarcoma
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Gliosarcoma
1
Glioblastoma
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Interventions
Doxorubicin
13
Ifosfamide
10
Radiotherapy
6
Sunitinib
3
pegfilgrastim
2
Trabectedin
2
Radiotherapy, Conformal
2
Nivolumab
2
Methotrexate
2
Ipilimumab
2
Imatinib Mesylate
2
Filgrastim
2
Etoposide
2
Cisplatin
2
Chemotherapy, Adjuvant
2
tremelimumab
1
temsirolimus
1
soblidotin
1
saracatinib
1
romidepsin
1
ribociclib
1
reolysin
1
perifosine
1
pembrolizumab
1
pazopanib
1
olaratumab
1
montanide ISA 51
1
liposomal doxorubicin
1
indolepropanol phosphate
1
exatecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Histiocytoma, Malignant Fibrous
×
olaratumab
×
Clear all
NCT02451943
2025-07-15
ANNOUNCE
Eli Lilly and Company
Phase 3
Completed
509 enrolled
23 charts